Abbott Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.

Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.30 per share, up from $1.21 per share in the year-ago period. Abbott Laboratories projects quarterly revenue of $11.4 billion, compared to $10.63 billion a year earlier, according to data from Benzinga Pro.

On Sept. 19, the company's board of directors declared a quarterly common dividend of 59 cents per share.

Abbott Laboratories shares fell 0.6% to close at $132.57 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• Citigroup analyst Joanne Wuensch maintained a Buy rating and cut the price target from $157 to $155 on July 18, 2025. This analyst has an accuracy rate of 72%.
• Raymond James analyst Jayson Bedford maintained an Outperform rating and cut the price target from $142 to $141 on July 18, 2025. This analyst has an accuracy rate of 66%.
• Mizuho analyst Anthony Petrone maintained a Neutral rating and cut the price target from $140 to $135 on July 18, 2025. This analyst has an accuracy rate of 63%.
• Jefferies analyst Matthew Taylor upgraded the stock from Hold to Buy and raised the price target from $143 to $145 on July 18, 2025. This analyst has an accuracy rate of 68%.
• BTIG analyst Marie Thibault maintained a Buy rating and cut the price target from $148 to $145 on July 18, 2025. This analyst has an accuracy rate of 64%.

Considering buying ABT stock? Here’s what analysts think:

Read This Next:

• Top 2 Tech & Telecom Stocks That May Implode This Month

Photo via Shutterstock